<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12044553</PMID><DateCompleted><Year>2002</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0168-1656</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of biotechnology</Title><ISOAbbreviation>J Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>258</EndPage><MedlinePgn>251-8</MedlinePgn></Pagination><Abstract><AbstractText>The virus removal of protein A affinity chromatography, inactivation capacity, acid pH and a combination of high temperature with a chaotropic agent was determined in this work. The model viruses studied were sendaivirus, human immunodeficency virus (HIV-IIIb), human poliovirus type-II, human herpesvirus I and canine parvovirus. The protein A affinity chromatography showed a maximum reduction factor of 8 logs in the case of viruses larger than 120 nm size, while for small viruses (18-30 nm) the maximum reduction factor was about 5 logs. Non viral inactivation was observed during the monoclonal antibody elution step. Low pH treatment showed a maximum inactivation factor of 7.1 logs for enveloped viruses. However, a weak inactivation factor (3.4 logs) was obtained for DNA nonenveloped viruses. The combination of high temperature with 3 M KSCN showed a high inactivation factor for all of the viruses studied. The total clearance factor was 23.1, 15.1, 13.6, 20.0 and 16.0 logs for sendaivirus, HIV-IIIb, human poliovirus type-II, human herpesvirus I and canine parvovirus, respectively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vald&#xe9;s</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Genetic Engineering and Biotechnology, Ave 31/158 and 190, PO Box 6162, Havana 10600, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibarra</LastName><ForeName>Neysi</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ruibal</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Beldarra&#xed;n</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Noa</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Alem&#xe1;n</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Padilla</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Qui&#xf1;ones</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Agraz</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Biotechnol</MedlineTA><NlmUniqueID>8411927</NlmUniqueID><ISSNLinking>0168-1656</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013205">Staphylococcal Protein A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002846" MajorTopicYN="N">Chromatography, Affinity</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004340" MajorTopicYN="N">Drug Contamination</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017992" MajorTopicYN="N">Parvovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029082" MajorTopicYN="N">Sendai virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013205" MajorTopicYN="N">Staphylococcal Protein A</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="Y">Vaccines, Synthetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2002</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12044553</ArticleId><ArticleId IdType="pmc">PMC7126170</ArticleId><ArticleId IdType="doi">10.1016/s0168-1656(02)00047-0</ArticleId><ArticleId IdType="pii">S0168165602000470</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agraz A, Qui&#xf1;ones Y, Exp&#xf3;sito N, Bre&#xf1;a F, Madruga Y, Pent&#xf3;n E, Herrera L. Adsorption&#x2013;desorption of recombinant hepatitis B surface antigen (r-HBsAg) from P. pastoris on diatomaceous earth matrix: optimization of parameters for purification. Biotechnol. Bioeng. 1993;42:1238&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">18609673</ArticleId></ArticleIdList></Reference><Reference><Citation>Agraz A, Duarte C.A, Costa L, P&#xe9;rez L, P&#xe1;ez R, Pujol V, Fontirrochi G.J. Immunoaffinity purification of recombinant hepatitis B surface antigen from yeast using a monoclonal antibody. J. Chromatogr. A. 1994;672:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8069398</ArticleId></ArticleIdList></Reference><Reference><Citation>The European Agency for the Evaluation of Medical Products, Human Medicines Evaluation Unit-CPMP Biotechnology Working Party, &#x2018;Note for Guidance on Virus Validation Studies: the Design, Contribution, and Interpretation of Studies Validating the Inactivation of Studies Validating the Inactivation and Removal of Viruses,&#x2019; (CPMP/BWP/268/95 Final Version 2, Canary Wharf, London, 1996).</Citation></Reference><Reference><Citation>Darling A.J, Spaltro J.J. Process validation for virus removal. Considerations for design of process studies and viral assays. Biopharm. 1996;10:42&#x2013;50.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez de Coss&#xed;o M.E, D&#xed;az T, Galv&#xe1;n A, Vald&#xe9;s R, Gonzalez E, Ayala M, D&#xed;az J, Bestagno M, Burrone O, Gavilondo J. Antigen recognition characteristics and comparative performance in immunoaffinity purification of two monoclonal antibodies specific for the hepatitis B virus surface antigen. J. Biotechnol. 1997;56:69&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9304870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman T.C. An analysis of clearance factor measurements performed by spiking experiments. Biopharm. 1991;4:39&#x2013;42.</Citation></Reference><Reference><Citation>Hardy E, Martinez E, Diago D, Diaz R, Gonzalez D, Herrera L. Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. J. Biotechnol. 2000;17:157&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">10682276</ArticleId></ArticleIdList></Reference><Reference><Citation>ICH Guideline. Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. March 1997.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Larzul D. Viral validation design of a manufacturing process. Dev. Biol. Standardization. 1999;99:139&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10404885</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe1;ez R, Agraz A, Herrera L. The recovery of hepatitis B virus surface antigen (HBsAg) from recombinant P. pastoris strain, disruption and precipitation studies. Acta Biotechnol. 1993;13:117&#x2013;122.</Citation></Reference><Reference><Citation>Pent&#xf3;n E, Herrera L, Muzio V, Ramirez V, Garc&#xed;a A, Duarte C, Ruiz C, Izquierdo M, P&#xe9;rez L, Fontirrochi G, Gonz&#xe1;lez M, Nazabal M, Beldarrain A, Padr&#xf3;n G, Garc&#xed;a J, de la Riva G, Santiago A, Ayan F, P&#xe1;ez R, Agraz A, D&#xed;az R, Qui&#xf1;ones Y. Method for obtaining recombinant surface antigen of hepatitis B virus of higher immunogenic capacity and use there of in vaccine preparation. Eur. Pat. Apl. 1992;480:525.</Citation></Reference><Reference><Citation>Pent&#xf3;n E, Muzio V, Griego-Gonz&#xe1;lez M. The hepatitis B virus (HBV) infection and its prevention by a recombinant&#x2014;DNA viral surface antigen (rec-HBsAg) vaccine. Biotecnol. Aplicada. 1994;11:1&#x2013;11.</Citation></Reference><Reference><Citation>Reed L.J, Muench H. A simple method for estimating fifty percent endpoints. Am. J. Hyg. 1938;27:439&#x2013;497.</Citation></Reference><Reference><Citation>Vald&#xe9;s R, Leyva J.L, Gonz&#xe1;lez E, Mainet D, Costa L. Caracterizaci&#xf3;n de Anticuerpos Monoclonales contra el Ant&#xed;geno de Superf&#xed;cie del Virus de la Hepatitis B. Biotecnol. Aplicada. 1994;11:219&#x2013;224.</Citation></Reference><Reference><Citation>Wampler D.E, Lehman E.D, Boger J, McAleer W.J, Scolnick E.M. Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc. Natl. Acad. Sci. USA. 1985;82:6830&#x2013;6834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390781</ArticleId><ArticleId IdType="pubmed">2931722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>